Stamford, CT (PRWEB) October 10, 2012 Mannkind recently announced that it has completed recruiting patients for two Phase 3 clinical studies of AFREZZA (insulin human [rDNA origin]), its investigational, ultra rapid-acting mealtime insulin therapy.

According to the company “Both studies are on track to be completed in the second quarter of 2013 and we expect to report top-line results next summer. Our objective is to resubmit the NDA for AFREZZA in the third quarter of next year.”

What this means for Mannkind investors, is that the waiting and dilution games continue, likely until next year. With a burn rate of roughly $8.5MM per quarter, the company will need to dilute the stock to fund trial conclusions and general operations. Should a pharmaceutical partner emerge for AFREZZA, the stock would appreciate considerably, but this unlikely also until at least next year, when results from the Phase III’s are in-hand.

As clinical trials continue on, watch for weaknesses in the stock, as several potential entry opportunities may arise throughout the next several months. Shares closed at $2.52 on 10/9/12. The trading range over the last 12 months has been $1.57-$3.62.

While the wait for AFREZZA seems ‘extreme’, the upside appreciation in share price could be as well, if Phase III results are positive, and a large pharma company joins the party.

Mannkind seems committed as ever in getting AFREZZA through the FDA process.

AFREZZA is a novel, ultra rapid acting mealtime insulin therapy being developed by MannKind Corporation for the treatment of adult patients with type 1 or type 2 diabetes for the control of hyperglycemia. It is a drug-device combination product, consisting of AFREZZA Inhalation Powder, pre-metered into single-use cartridges, and a light, discreet and easy-to-use inhaler

http://news.yahoo.com/otc-stock-picks-newsletter-announces-awesome-penny-stock-131218011.html